Quality of life in poor prognosis patients with locally advanced non-small cell lung cancer (LA-NSCLC) undergoing a phase II study of concurrent cetuximab and definitive thoracic radiotherapy followed by docetaxel and cetuximab.
Lora Thompson
No relevant relationships to disclose
Martine Extermann
Consultant or Advisory Role - GTx
Honoraria - Amgen; Sanofi
Thomas J. Dilling
No relevant relationships to disclose
Jongphil Kim
No relevant relationships to disclose
Binglin Yue
No relevant relationships to disclose
Craig William Stevens
No relevant relationships to disclose
Scott Antonia
No relevant relationships to disclose
Jhanelle Elaine Gray
No relevant relationships to disclose
Charles C. Williams
No relevant relationships to disclose
Eric B. Haura
No relevant relationships to disclose
Mary Colleen Pinder
No relevant relationships to disclose
Tawee Tanvetyanon
No relevant relationships to disclose
Alberto Chiappori
Honoraria - Lilly